Clinicopathological and prognostic evaluations of anorectal cancer after fecal diversion for patients with Crohn’s disease

Table 2 Outcomes in patients with diverted anorectal cancer after APR

Patient	Resected margin	Type of histology	TNM classification	Chemoradiation	Site of recurrence	Outcome after cancer diagnosis
1	Negative	muc	Stage II	Chemotherapy	Intrapelvic, uterus	Dead at 32 months
2	Negative	muc	Stage II	Chemoradiation	Intrapelvic, inguinal LN	Dead at 45 months
3	Negative	muc, sig	Stage IV	Chemotherapy	Peritoneal dissemination	Dead at 26 months
4	Negative	w/d, m/d	Stage I	Nothing	NED	Alive at 60 months
5	Negative	por, w/d, and m/d	Stage IV	Chemotherapy	Intrapelvic, peritoneal dissemination	Dead at 27 months
6	Positive	muc, sig	Stage III	Chemotherapy	Intrapelvic, bone	Dead at 20 months
7	Negative	m/d	Stage II	Chemoradiation	Intrapelvic, bone	Dead at 36 months
8	Negative	muc, sig, and w/d	Stage II	Chemotherapy	Intrapelvic, paraaortic LN	Dead at 30 months
9	Positive	muc	Stage II	Chemoradiation, heavy ion radiotherapy	Intrapelvic	Alive at 110 months
10	Positive	muc, sig, and w/d	Stage II	Chemotherapy	Intrapelvic	Dead at 3 months

APR abdominoperineal resection, LN lymph node, m/d moderately differentiated adenocarcinoma, muc mucinous adenocarcinoma, NED no evidence of disease, por poorly differentiated adenocarcinoma, sig signet ring, w/d well-differentiated adenocarcinoma

ISSN: 1471-230X